Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
MicroVision Inc

Start price
Target price
Perf. (%)
€12.65
08.07.21
-
08.07.22
-62.55%
08.07.22

buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€77.90
08.07.21
-
08.07.22
-46.53%
08.07.22

buy
Stratec SE

Start price
Target price
Perf. (%)
€117.40
08.07.21
-
08.07.22
-19.51%
08.07.22

buy
Agfa Gevaert N.V.

Start price
Target price
Perf. (%)
€3.90
08.07.21
-
08.07.22
-11.17%
08.07.22

buy
ShockWave Medical Inc

Start price
Target price
Perf. (%)
€159.00
16.06.21
€225.00
16.06.22
-5.66%
16.06.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
buy
CareCloud Inc.

Start price
Target price
Perf. (%)
€7.30
12.06.21
-
12.06.22
-55.62%
12.06.22

buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€49.15
01.06.22
-
01.06.23
-2.34%
11.06.22

Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Revenue growth > 30% per year expected
buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€42.25
01.06.22
-
01.06.23
-0.47%
11.06.22

Fair valuation
Top 10 in its market
Future proof or reliable business model
Could be worthwhile Investment >10% per year
buy
Geratherm Medical AG

Start price
Target price
Perf. (%)
€9.46
03.10.21
-
03.10.22
-10.78%
04.06.22

Could be very worthwhile Investment >20% year
Bovie Medical Corp

Start price
Target price
Perf. (%)
€6.45
20.03.22
-
20.03.23
-8.53%
28.05.22

Risky Investment
buy
Vita 34 AG

Start price
Target price
Perf. (%)
€11.05
18.05.22
-
18.05.23
-0.45%
28.05.22

Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€75.60
26.05.21
€82.00
26.05.22
-36.11%
27.05.22

Edap Tms S.A. ADR

Start price
Target price
Perf. (%)
€5.00
03.01.22
-
03.01.23
27.00%
15.05.22

Probably not worthwhile Investment
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€74.55
07.05.21
€60.00
07.05.22
-37.42%
08.05.22

Higher EBIT margin than peer group
Probably not worthwhile Investment
Low dividend yield expected
Below average Management
Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€81.20
03.05.21
€75.00
03.05.22
-41.82%
04.05.22

Could be worthwhile Investment >10% per year
buy
Motus GI Holdings Inc.

Start price
Target price
Perf. (%)
€23.00
02.05.21
-
02.05.22
-82.60%
03.05.22

Could be worthwhile Investment >10% per year
buy
Stratec SE

Start price
Target price
Perf. (%)
€116.60
03.03.21
€165.00
03.10.22
3.43%
06.04.22

Could be worthwhile Investment >10% per year
buy
Mediclin AG

Start price
Target price
Perf. (%)
€3.32
07.03.22
-
07.03.23
0.60%
19.03.22

EBIT growth >5% per year expected
positive Cash Flow expected
Top 10 in its market
Future proof or reliable business model
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€9.50
01.10.21
-
01.10.22
-58.63%
13.03.22

Vivani Medical Inc.

Start price
Target price
Perf. (%)
€26.55
10.03.21
-
10.03.22
-86.89%
11.03.22

Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€61.80
08.03.21
-
08.03.22
-21.91%
09.03.22

buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€61.80
08.03.21
-
08.03.22
-26.29%
09.03.22

buy
Harvard Bioscience

Start price
Target price
Perf. (%)
€6.50
27.07.21
-
27.07.22
-25.54%
02.03.22

buy
Castlight Healt.b

Start price
Target price
Perf. (%)
€1.85
23.07.21
-
23.07.22
-4.32%
02.03.22

buy
Vita 34 AG

Start price
Target price
Perf. (%)
€15.55
21.02.21
-
21.02.22
-25.08%
22.02.22

Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected